The estimated Net Worth of Denise Bevers is at least $77.7 Mille dollars as of 17 March 2021. Denise Bevers owns over 8,396 units of Kindred Biosciences Inc stock worth over $77,663 and over the last 11 years Denise sold KIN stock worth over $0.
Sign up
Denise Bevers KIN stock SEC Form 4 insiders trading
Denise has made over 8 trades of the Kindred Biosciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Denise exercised 8,396 units of KIN stock worth $2,687 on 17 March 2021.
The largest trade Denise's ever made was exercising 95,000 units of Kindred Biosciences Inc stock on 31 July 2020 worth over $878,750. On average, Denise trades about 10,032 units every 21 days since 2014. As of 17 March 2021 Denise still owns at least 8,396 units of Kindred Biosciences Inc stock.
You can see the complete history of Denise Bevers stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Denise Bevers's mailing address?
Denise's mailing address filed with the SEC is C/O KINDRED BIOSCIENCES, INC., 1555 BAYSHORE HIGHWAY, SUITE 200, BURLINGAME, CA, 94010.
Insiders trading at Kindred Biosciences Inc
Over the last 11 years, insiders at Kindred Biosciences Inc have traded over $10,542,886 worth of Kindred Biosciences Inc stock and bought 50,952,388 units worth $461,948,778 . The most active insiders traders include Animal Health Inc Elanco, West Asset Management Llc Park e Ernest Mario. On average, Kindred Biosciences Inc executives and independent directors trade stock every 34 days with the average trade being worth of $5,949,674. The most recent stock trade was executed by Animal Health Inc Elanco on 27 August 2021, trading 45,508,938 units of KIN stock currently worth $420,957,677.
What does Kindred Biosciences Inc do?
Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio.
What does Kindred Biosciences Inc's logo look like?
Complete history of Denise Bevers stock trades at Kindred Biosciences Inc
Kindred Biosciences Inc executives and stock owners
Kindred Biosciences Inc executives and other stock owners filed with the SEC include:
-
Krystian Dejk,
Chairman of the Management Board -
Halina Kleba,
Member of the Supervisory Board -
Bartlomiej Weglewski,
Chairman of the Supervisory Board -
Krzysztof Kochanowski,
Member of the Supervisory Board -
Hanna Smolinska,
Member of the Supervisory Board -
Lukasz Cieslak,
Member of the Supervisory Board -
Raymond Townsend,
Director -
Ernest Mario,
Director -
Stephen Sundlof,
SVP of Regulatory Affairs -
Ervin Veszpremi,
Director -
Herbert D Montgomery,
Director -
West Asset Management Llc Park,
10% owner -
Wendy Wee,
Chief Financial Officer -
Hangjun Zhan,
Chief Scientific Officer -
Denise Bevers,
Director -
Selby Blake Hawley,
Chief Commercial Officer -
Joseph S Mc Cracken,
Director -
Oleg Nodelman,
Director -
Kevin Schultz,
Chief Scientific Officer -
Stephen S Galliker,
Chief Financial Officer -
Richard Chin,
Chief Executive Officer -
Lyndon Lien,
Director -
Nanxi Liu,
Director -
Animal Health Inc Elanco,
10% owner